1st World Bronchiectasis Conference

Abdelrahman, S

MDCT severity score of bronchiectasis in correlation with pulmonary function tests

Abo-Leyah, H

Anti-Pseudomonas aeruginosa IgG Antibodies and Chronic Airway Infection in Non-Cystic Fibrosis Bronchiectasis

Abu Rmeileh, A

STAT3-gain of function mutation as a cause of severe bronchiectasis and multi-organ autoimmunity; A case report

Adir, Y

Bronchiectasis with upper airways symptoms is associated with allergic features and frequent exacerbations

Aggarwal, N

Why do some adults with PiMZ alpha1-antitrypin develop bronchiectasis?

Aksamit, T

Baseline therapies for Bronchiectasis (non-CF etiology) vary by country – data from the RESPIRE1 trial of Ciprofloxacin Dry Powder for Inhalation (DPI)

Alcaraz-Serrano, V

Pneumonic vs. non-pneumonic exacerbations in bronchiectasis

Exacerbations by Pseudomonas aeruginosa in patients with bronchiectasis

Effects of hypertonic saline on sputum clearance in patients with bronchiectasis

Evaluation of two prognostic scores in adult patients with non-cystic fibrosis bronchiectasis

Alevra, M

TAp73 is a central transcriptional regulator of airway multiciliogenesis and protects bronchial function

Aliberti, S

Editorial

Characterization of bronchiectasis in the elderly

Altenburg, J

Effects of long term ToBrAmycin InhalaTion SoluTion (TIS) once daiLy on Exacerbation rate in patients with non-cystic fibrosis bronchiectasis. A doubleblind, randomized, placebo controlled trial. The BATTLE study.

The relationship between serum- and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment

Alvarez, A

Long-term randomized controlled trial to evaluate the efficacy of low expiration with the open glottis in the lateral posture in bronchiectasis

Amara-Elori, I

Risk factors for bronchiectasis exacerbations caused by multidrug-resistant microorganisms

Amorim, A

Non-tuberculous mycobacteria in patients with non-cystic fibrosis bronchiectasis – a prospective analysis

Ansotegui, E

Pneumonic vs. non-pneumonic exacerbations in bronchiectasis

Exacerbations by Pseudomonas aeruginosa in patients with bronchiectasis

Araújo, D

Non-tuberculous mycobacteria in patients with non-cystic fibrosis bronchiectasis – a prospective analysis

Ausubel, F

A Novel Combination of Tobramycin with a Potentiator for the Treatment of Chronic Pseudomonas aeruginosa Infections

Bals, R

TAp73 is a central transcriptional regulator of airway multiciliogenesis and protects bronchial function

Bandel, TJ

Baseline therapies for Bronchiectasis (non-CF etiology) vary by country – data from the RESPIRE1 trial of Ciprofloxacin Dry Powder for Inhalation (DPI)

Barker, AF

Inhaled antibiotics: potential and pitfalls

Barrecheguren, M

Prevalence of bronchiectasis in four European countries

Barten, G

PROGNOSIS – the German Bronchiectasis Registry

Bellelli, G

Characterization of bronchiectasis in the elderly

Berkman, N

STAT3-gain of function mutation as a cause of severe bronchiectasis and multi-organ autoimmunity; A case report

Bilton, D

A Phase 3 Study Design of Pulmaquin® in Non-Cystic Fibrosis Bronchiectasis (NCFBE) Patients Chronically Colonized with Pseudomonas aeruginosa (PA)

Pseudomonas aeruginosa diversity and adaptation in the non-Cystic Fibrosis bronchiectasis lung

Blanchette, C

Treatment patterns associated with pseudomonas aeruginosa among patients with non-cystic fibrosis bronchiectasis in the US

The prevalence of non-cystic fibrosis bronchiectasis in the US

Healthcare cost and utilization before and after diagnosis of pseudomonas aeruginosa among patients with non-cystic fibrosis bronchiectasis in the US

Boersma, W

Effects of long term ToBrAmycin InhalaTion SoluTion (TIS) once daiLy on Exacerbation rate in patients with non-cystic fibrosis bronchiectasis. A doubleblind, randomized, placebo controlled trial. The BATTLE study.

The relationship between serum- and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment

Bonn, S

TAp73 is a central transcriptional regulator of airway multiciliogenesis and protects bronchial function

Boskovic, T

The incidence of metabolic syndrome in patients with non-CF bronchiectasis and chronic obstructive pulmonary disease

Computed tomography features in patients with non-cystic fibrosis bronchiectasis and COPD – one Institution experience

Bossuyt, X

Sensitization to Aspergillus fumigatus in COPD patients with and without bronchiectasis

Botnaru, V

Combination of non CF-bronchiectasis and calcifications: a hallmark of high burden TB country

Braun, S

Prevalence of bronchiectasis in four European countries

Brown-Elliott, B

12-Month Follow-up From Phase 2 Trial of Liposomal Amikacin for Inhalation (LAI) in Patients With Nontuberculous Mycobacterial (NTM) Lung Infection

Bruinenberg, P

A Phase 3 Study Design of Pulmaquin® in Non-Cystic Fibrosis Bronchiectasis (NCFBE) Patients Chronically Colonized with Pseudomonas aeruginosa (PA)

Buxó, M

Long-term randomized controlled trial to evaluate the efficacy of low expiration with the open glottis in the lateral posture in bronchiectasis

Calderazzo, MA

CHI25243, a novel potent inhaled inhibitor of neutrophil elastase for the treatment of bronchiectasis and other chronic inflammatory lung disease

Carnini, C

CHI25243, a novel potent inhaled inhibitor of neutrophil elastase for the treatment of bronchiectasis and other chronic inflammatory lung disease

Carvalho, T

Non-tuberculous mycobacteria in patients with non-cystic fibrosis bronchiectasis – a prospective analysis

Chalmers, J

Editorial

Chalmers, JD

Omics approaches to understand airway inflammation in bronchiectasis

Anti-Pseudomonas aeruginosa IgG Antibodies and Chronic Airway Infection in Non-Cystic Fibrosis Bronchiectasis

Characterization of bronchiectasis in the elderly

Chrysikos, S

Hyper IgE Syndrome: a rare cause of bronchiectasis

Cisneros, C

Pneumonic vs. non-pneumonic exacerbations in bronchiectasis

Exacerbations by Pseudomonas aeruginosa in patients with bronchiectasis

Civelli, M

CHI25243, a novel potent inhaled inhibitor of neutrophil elastase for the treatment of bronchiectasis and other chronic inflammatory lung disease

Criollo, M

Baseline therapies for Bronchiectasis (non-CF etiology) vary by country – data from the RESPIRE1 trial of Ciprofloxacin Dry Powder for Inhalation (DPI)

Dagan, A

Effect of professional physiotherapy on patients with non CF bronchiectasis – a preliminary study

Davies, G

Plasmapheresis as rescue therapy in severe bronchiectasis with blocking anti pseudomonas antibodies

Davison, J

Plasmapheresis as rescue therapy in severe bronchiectasis with blocking anti pseudomonas antibodies

Pneumococcal vaccination in bronchiectasis- an area for improvement?

Pulmonary targeted antibiotics in bronchiectasis; inhalers vs. nebulisers. A qualitative and quantitative assessment of patients' attitudes.

de Gracia, J

Long-term randomized controlled trial to evaluate the efficacy of low expiration with the open glottis in the lateral posture in bronchiectasis

de Roux, A

Prevalence of Nontuberculous Mycobacterial Pulmonary Disease, Germany, 2009 – 2014

PROGNOSIS – the German Bronchiectasis Registry

Deskata, K

Hyper IgE Syndrome: a rare cause of bronchiectasis

De Soyza, A

Living your life with bronchiectasis. Qualitative interviews inform the development and evaluation of a novel information resource.

Baseline therapies for Bronchiectasis (non-CF etiology) vary by country – data from the RESPIRE1 trial of Ciprofloxacin Dry Powder for Inhalation (DPI)

Plasmapheresis as rescue therapy in severe bronchiectasis with blocking anti pseudomonas antibodies

Pseudomonas aeruginosa diversity and adaptation in the non-Cystic Fibrosis bronchiectasis lung

Pneumococcal vaccination in bronchiectasis- an area for improvement?

De Soyza, T

Pulmonary targeted antibiotics in bronchiectasis; inhalers vs. nebulisers. A qualitative and quantitative assessment of patients' attitudes.

Diel, R

Prevalence of Nontuberculous Mycobacterial Pulmonary Disease, Germany, 2009 – 2014

PROGNOSIS – the German Bronchiectasis Registry

Dimakou, K

Characterization of bronchiectasis in the elderly

Hyper IgE Syndrome: a rare cause of bronchiectasis

Djuric, M

The incidence of metabolic syndrome in patients with non-CF bronchiectasis and chronic obstructive pulmonary disease

Computed tomography features in patients with non-cystic fibrosis bronchiectasis and COPD – one Institution experience

Dönitz, J

TAp73 is a central transcriptional regulator of airway multiciliogenesis and protects bronchial function

Dore, S

Characterization of bronchiectasis in the elderly

Dragisic, D

Computed tomography features in patients with non-cystic fibrosis bronchiectasis and COPD – one Institution experience

Drivas, G

Hyper IgE Syndrome: a rare cause of bronchiectasis

Dupont, L

Sensitization to Aspergillus fumigatus in COPD patients with and without bronchiectasis

Lost in translation? Therapeutic contrasts in CF and non-CF bronchiectasis

Eagle, G

12-Month Follow-up From Phase 2 Trial of Liposomal Amikacin for Inhalation (LAI) in Patients With Nontuberculous Mycobacterial (NTM) Lung Infection

Efrati, O

Effect of professional physiotherapy on patients with non CF bronchiectasis – a preliminary study

Elborn, JS

Baseline therapies for Bronchiectasis (non-CF etiology) vary by country – data from the RESPIRE1 trial of Ciprofloxacin Dry Powder for Inhalation (DPI)

Molecular diagnosis of infection and resistance

Elnekeidy, A

MDCT severity score of bronchiectasis in correlation with pulmonary function tests

Elpeleg, O

STAT3-gain of function mutation as a cause of severe bronchiectasis and multi-organ autoimmunity; A case report

Eshenkulova, V

Problems of diagnosis and treatment of bronchiectasis in Kyrgyz Republic in conditions of limited health care resources

Everaerts, S

Sensitization to Aspergillus fumigatus in COPD patients with and without bronchiectasis

Fardon, TC

Anti-Pseudomonas aeruginosa IgG Antibodies and Chronic Airway Infection in Non-Cystic Fibrosis Bronchiectasis

Characterization of bronchiectasis in the elderly

Finch, H

CHI25243, a novel potent inhaled inhibitor of neutrophil elastase for the treatment of bronchiectasis and other chronic inflammatory lung disease

Fitzgerald, M

CHI25243, a novel potent inhaled inhibitor of neutrophil elastase for the treatment of bronchiectasis and other chronic inflammatory lung disease

Fothergill, J

Pseudomonas aeruginosa diversity and adaptation in the non-Cystic Fibrosis bronchiectasis lung

Foweraker, J

Pseudomonas aeruginosa diversity and adaptation in the non-Cystic Fibrosis bronchiectasis lung

Fox, B

Lobar Distribution in Non-Cystic Fibrosis Bronchiectasis Predicts Bacteriologic Pathogen Treatment

Fox, C

CHI25243, a novel potent inhaled inhibitor of neutrophil elastase for the treatment of bronchiectasis and other chronic inflammatory lung disease

Froehlich, J

A Phase 3 Study Design of Pulmaquin® in Non-Cystic Fibrosis Bronchiectasis (NCFBE) Patients Chronically Colonized with Pseudomonas aeruginosa (PA)

Fruchter, O

Lobar Distribution in Non-Cystic Fibrosis Bronchiectasis Predicts Bacteriologic Pathogen Treatment

Fuks, L

Lobar Distribution in Non-Cystic Fibrosis Bronchiectasis Predicts Bacteriologic Pathogen Treatment

Gallinas Suazo, C

TAp73 is a central transcriptional regulator of airway multiciliogenesis and protects bronchial function

García Rodríguez, LA

Prevalence of bronchiectasis in four European countries

Gerbeshian, E

Bronchiectasis with upper airways symptoms is associated with allergic features and frequent exacerbations

Girón, RM

Pneumonic vs. non-pneumonic exacerbations in bronchiectasis

Exacerbations by Pseudomonas aeruginosa in patients with bronchiectasis

Glaser, K

TAp73 is a central transcriptional regulator of airway multiciliogenesis and protects bronchial function

Goeminne, PC

Characterization of bronchiectasis in the elderly

Gonda, I

A Phase 3 Study Design of Pulmaquin® in Non-Cystic Fibrosis Bronchiectasis (NCFBE) Patients Chronically Colonized with Pseudomonas aeruginosa (PA)

González-Pérez, A

Prevalence of bronchiectasis in four European countries

Griffith, D

12-Month Follow-up From Phase 2 Trial of Liposomal Amikacin for Inhalation (LAI) in Patients With Nontuberculous Mycobacterial (NTM) Lung Infection

Gutu, A

A Novel Combination of Tobramycin with a Potentiator for the Treatment of Chronic Pseudomonas aeruginosa Infections

Haas, J

Prevalence of bronchiectasis in four European countries

Hamm, M

Intrapulmonary percussive ventilation, indication, clinical experience and patient opinion

Haworth, CS

Pseudomonas aeruginosa diversity and adaptation in the non-Cystic Fibrosis bronchiectasis lung

Henderson, I

Plasmapheresis as rescue therapy in severe bronchiectasis with blocking anti pseudomonas antibodies

Hennion, M

TAp73 is a central transcriptional regulator of airway multiciliogenesis and protects bronchial function

Herr, C

TAp73 is a central transcriptional regulator of airway multiciliogenesis and protects bronchial function

Herrero-Cortina, B

Effects of hypertonic saline on sputum clearance in patients with bronchiectasis

Hester, K

Living your life with bronchiectasis. Qualitative interviews inform the development and evaluation of a novel information resource.

Hickstein, L

Prevalence of Nontuberculous Mycobacterial Pulmonary Disease, Germany, 2009 – 2014

Hilliam, Y

Pseudomonas aeruginosa diversity and adaptation in the non-Cystic Fibrosis bronchiectasis lung

Hohmann, D

Prevalence of Nontuberculous Mycobacterial Pulmonary Disease, Germany, 2009 – 2014

Holland, A

An interactive educational website for the management of bronchiectasis: The Bronchiectasis Toolbox

Howden, R

Treatment patterns associated with pseudomonas aeruginosa among patients with non-cystic fibrosis bronchiectasis in the US

The prevalence of non-cystic fibrosis bronchiectasis in the US

Healthcare cost and utilization before and after diagnosis of pseudomonas aeruginosa among patients with non-cystic fibrosis bronchiectasis in the US

Hurst, J

COPD and bronchiectasis – a real phenotype?

Ilan, Y

STAT3-gain of function mutation as a cause of severe bronchiectasis and multi-organ autoimmunity; A case report

Iso-Mustajärvi, I

Prevalence of bronchiectasis in four European countries

Izhakian, S

Lobar Distribution in Non-Cystic Fibrosis Bronchiectasis Predicts Bacteriologic Pathogen Treatment

Jakubec, P

Study of population of patients with non-cystic bronchiectasis treated in the University Hospital of Olomouc, Czech Republic

Janciauskiene, S

Why do some adults with PiMZ alpha1-antitrypin develop bronchiectasis?

Janssens, W

Sensitization to Aspergillus fumigatus in COPD patients with and without bronchiectasis

Joseph-McCarthy, D

A Novel Combination of Tobramycin with a Potentiator for the Treatment of Chronic Pseudomonas aeruginosa Infections

Juelich, F

Prevalence of bronchiectasis in four European countries

Kanagasundaram, S

Plasmapheresis as rescue therapy in severe bronchiectasis with blocking anti pseudomonas antibodies

Kaponi, M

Hyper IgE Syndrome: a rare cause of bronchiectasis

Karadzinska Bislimovska, J

Frequency and severity of chronic rhinosinusitis exacerbations in patients with bronchiectasis

Kardos, P

Pulmonary Nocardiosis in a Non-Immuncompromised Patient with Bronchiectasis

Kausar, S

Antibiotic use in treatment of non-CF Bronchiectasis: A retrospective analysis

Khalid, S

Antibiotic use in treatment of non-CF Bronchiectasis: A retrospective analysis

Khoury, T

STAT3-gain of function mutation as a cause of severe bronchiectasis and multi-organ autoimmunity; A case report

Koeva, M

A Novel Combination of Tobramycin with a Potentiator for the Treatment of Chronic Pseudomonas aeruginosa Infections

Kolek, V

Study of population of patients with non-cystic bronchiectasis treated in the University Hospital of Olomouc, Czech Republic

Korfmann, G

Prevalence of bronchiectasis in four European countries

Kramer, D

TAp73 is a central transcriptional regulator of airway multiciliogenesis and protects bronchial function

Kramer, M

Lobar Distribution in Non-Cystic Fibrosis Bronchiectasis Predicts Bacteriologic Pathogen Treatment

Kuint, R

STAT3-gain of function mutation as a cause of severe bronchiectasis and multi-organ autoimmunity; A case report

Lagrou, K

Sensitization to Aspergillus fumigatus in COPD patients with and without bronchiectasis

Lamont, I

Pseudomonas aeruginosa diversity and adaptation in the non-Cystic Fibrosis bronchiectasis lung

Lane, N

Pneumococcal vaccination in bronchiectasis- an area for improvement?

Lee, A

An interactive educational website for the management of bronchiectasis: The Bronchiectasis Toolbox

Lee, R

Pulmonary targeted antibiotics in bronchiectasis; inhalers vs. nebulisers. A qualitative and quantitative assessment of patients' attitudes.

Lin, JL

Bronchiectasis in China: Present Situations and Challenges

Lizé, M

TAp73 is a central transcriptional regulator of airway multiciliogenesis and protects bronchial function

Lombi, A

Characterization of bronchiectasis in the elderly

Lu, HW

The existence of asthma increases bronchiectasis exacerbation

MacLennan, CA

Plasmapheresis as rescue therapy in severe bronchiectasis with blocking anti pseudomonas antibodies

Mao, B

The existence of asthma increases bronchiectasis exacerbation

Mapel, D

Treatment patterns associated with pseudomonas aeruginosa among patients with non-cystic fibrosis bronchiectasis in the US

The prevalence of non-cystic fibrosis bronchiectasis in the US

Healthcare cost and utilization before and after diagnosis of pseudomonas aeruginosa among patients with non-cystic fibrosis bronchiectasis in the US

Marcos, MA

Pneumonic vs. non-pneumonic exacerbations in bronchiectasis

Exacerbations by Pseudomonas aeruginosa in patients with bronchiectasis

Marosis, K

Hyper IgE Syndrome: a rare cause of bronchiectasis

Martinez Delgado Delgado, B

Why do some adults with PiMZ alpha1-antitrypin develop bronchiectasis?

Matamala, N

Why do some adults with PiMZ alpha1-antitrypin develop bronchiectasis?

McDonnell, MJ

Characterization of bronchiectasis in the elderly

McEvoy, D

Pneumococcal vaccination in bronchiectasis- an area for improvement?

Pulmonary targeted antibiotics in bronchiectasis; inhalers vs. nebulisers. A qualitative and quantitative assessment of patients' attitudes.

McGinnis, J

12-Month Follow-up From Phase 2 Trial of Liposomal Amikacin for Inhalation (LAI) in Patients With Nontuberculous Mycobacterial (NTM) Lung Infection

Mehtälä, J

Prevalence of bronchiectasis in four European countries

Meister, W

Intrapulmonary percussive ventilation, indication, clinical experience and patient opinion

Méndez, R

Risk factors for bronchiectasis exacerbations caused by multidrug-resistant microorganisms

Menendez, R

Pneumonic vs. non-pneumonic exacerbations in bronchiectasis

Exacerbations by Pseudomonas aeruginosa in patients with bronchiectasis

Menéndez, R

Risk factors for bronchiectasis exacerbations caused by multidrug-resistant microorganisms

Meyne, N

Intrapulmonary percussive ventilation, indication, clinical experience and patient opinion

Miglietta, D

CHI25243, a novel potent inhaled inhibitor of neutrophil elastase for the treatment of bronchiectasis and other chronic inflammatory lung disease

Mijakoski, D

Frequency and severity of chronic rhinosinusitis exacerbations in patients with bronchiectasis

Milenkovic, B

Presentation of Yellow Nail Syndrome in a two female patients Milenkovic B, Cvejic J, Dimic Janjic S

Minov, J

Frequency and severity of chronic rhinosinusitis exacerbations in patients with bronchiectasis

Miravitlles, M

Prevalence of bronchiectasis in four European countries

Molho-Pessach, V

STAT3-gain of function mutation as a cause of severe bronchiectasis and multi-organ autoimmunity; A case report

Moll, U

TAp73 is a central transcriptional regulator of airway multiciliogenesis and protects bronchial function

Monteagudo, M

Prevalence of bronchiectasis in four European countries

Montull, B

Pneumonic vs. non-pneumonic exacerbations in bronchiectasis

Exacerbations by Pseudomonas aeruginosa in patients with bronchiectasis

Moore, M

Pseudomonas aeruginosa diversity and adaptation in the non-Cystic Fibrosis bronchiectasis lung

Müller, G

Intrapulmonary percussive ventilation, indication, clinical experience and patient opinion

Muñoz, G

Pneumonic vs. non-pneumonic exacerbations in bronchiectasis

Exacerbations by Pseudomonas aeruginosa in patients with bronchiectasis

Long-term randomized controlled trial to evaluate the efficacy of low expiration with the open glottis in the lateral posture in bronchiectasis

Munteanu, O

Combination of non CF-bronchiectasis and calcifications: a hallmark of high burden TB country

Nasrallah, N

Bronchiectasis with upper airways symptoms is associated with allergic features and frequent exacerbations

Nemajerova, A

TAp73 is a central transcriptional regulator of airway multiciliogenesis and protects bronchial function

Newton, J

Living your life with bronchiectasis. Qualitative interviews inform the development and evaluation of a novel information resource.

Nicolson, C

An interactive educational website for the management of bronchiectasis: The Bronchiectasis Toolbox

Noone, J

Treatment patterns associated with pseudomonas aeruginosa among patients with non-cystic fibrosis bronchiectasis in the US

The prevalence of non-cystic fibrosis bronchiectasis in the US

Healthcare cost and utilization before and after diagnosis of pseudomonas aeruginosa among patients with non-cystic fibrosis bronchiectasis in the US

O'Donnell, A

A Phase 3 Study Design of Pulmaquin® in Non-Cystic Fibrosis Bronchiectasis (NCFBE) Patients Chronically Colonized with Pseudomonas aeruginosa (PA)

Oberle, F

TAp73 is a central transcriptional regulator of airway multiciliogenesis and protects bronchial function

Obradovic, D

The incidence of metabolic syndrome in patients with non-CF bronchiectasis and chronic obstructive pulmonary disease

Characterization of bronchiectasis in the elderly

Olivier, K

12-Month Follow-up From Phase 2 Trial of Liposomal Amikacin for Inhalation (LAI) in Patients With Nontuberculous Mycobacterial (NTM) Lung Infection

Onn, A

Effect of professional physiotherapy on patients with non CF bronchiectasis – a preliminary study

Operschall, E

Baseline therapies for Bronchiectasis (non-CF etiology) vary by country – data from the RESPIRE1 trial of Ciprofloxacin Dry Powder for Inhalation (DPI)

Palmer, E

Pneumococcal vaccination in bronchiectasis- an area for improvement?

Pane, F

Characterization of bronchiectasis in the elderly

Patacchini, R

CHI25243, a novel potent inhaled inhibitor of neutrophil elastase for the treatment of bronchiectasis and other chronic inflammatory lung disease

Pena, T

TAp73 is a central transcriptional regulator of airway multiciliogenesis and protects bronchial function

Pena Karan, S

Computed tomography features in patients with non-cystic fibrosis bronchiectasis and COPD – one Institution experience

Pesci, A

Characterization of bronchiectasis in the elderly

Plaza, V

Anti-Pseudomonas aeruginosa IgG Antibodies and Chronic Airway Infection in Non-Cystic Fibrosis Bronchiectasis

Polverino, E

Risk factors for bronchiectasis exacerbations caused by multidrug-resistant microorganisms

Baseline therapies for Bronchiectasis (non-CF etiology) vary by country – data from the RESPIRE1 trial of Ciprofloxacin Dry Powder for Inhalation (DPI)

Editorial

Pneumonic vs. non-pneumonic exacerbations in bronchiectasis

Asthma and bronchiectasis

Exacerbations by Pseudomonas aeruginosa in patients with bronchiectasis

Effects of hypertonic saline on sputum clearance in patients with bronchiectasis

Evaluation of two prognostic scores in adult patients with non-cystic fibrosis bronchiectasis

Posadas, T

Risk factors for bronchiectasis exacerbations caused by multidrug-resistant microorganisms

Povazan, D

The incidence of metabolic syndrome in patients with non-CF bronchiectasis and chronic obstructive pulmonary disease

Computed tomography features in patients with non-cystic fibrosis bronchiectasis and COPD – one Institution experience

Puviani, V

CHI25243, a novel potent inhaled inhibitor of neutrophil elastase for the treatment of bronchiectasis and other chronic inflammatory lung disease

Qu, JM

Bronchiectasis in China: Present Situations and Challenges

Quittner, A

Quality of life as an outcome measure in clinical trials

Rademacher, J

Why do some adults with PiMZ alpha1-antitrypin develop bronchiectasis?

Prevalence of Nontuberculous Mycobacterial Pulmonary Disease, Germany, 2009 – 2014

PROGNOSIS – the German Bronchiectasis Registry

Raguer, L

Exacerbations by Pseudomonas aeruginosa in patients with bronchiectasis

Evaluation of two prognostic scores in adult patients with non-cystic fibrosis bronchiectasis

Ramadan, R

MDCT severity score of bronchiectasis in correlation with pulmonary function tests

Ramos, A

Non-tuberculous mycobacteria in patients with non-cystic fibrosis bronchiectasis – a prospective analysis

Ramot, Y

STAT3-gain of function mutation as a cause of severe bronchiectasis and multi-organ autoimmunity; A case report

Rapley, T

Living your life with bronchiectasis. Qualitative interviews inform the development and evaluation of a novel information resource.

Pulmonary targeted antibiotics in bronchiectasis; inhalers vs. nebulisers. A qualitative and quantitative assessment of patients' attitudes.

Redondo, M

Non-tuberculous mycobacteria in patients with non-cystic fibrosis bronchiectasis – a prospective analysis

Ribeiro, M

Non-tuberculous mycobacteria in patients with non-cystic fibrosis bronchiectasis – a prospective analysis

Riedel, D

TAp73 is a central transcriptional regulator of airway multiciliogenesis and protects bronchial function

Ringshausen, FC

Editorial

Why do some adults with PiMZ alpha1-antitrypin develop bronchiectasis?

Prevalence of Nontuberculous Mycobacterial Pulmonary Disease, Germany, 2009 – 2014

Non-CF bronchiectasis: a spectrum of CFTR (and ENaC) dysfunction?

PROGNOSIS – the German Bronchiectasis Registry

Prevalence of bronchiectasis in four European countries

Rizk, A

MDCT severity score of bronchiectasis in correlation with pulmonary function tests

Rodrigo-Troyano, A

Anti-Pseudomonas aeruginosa IgG Antibodies and Chronic Airway Infection in Non-Cystic Fibrosis Bronchiectasis

Rodríguez, T

Prevalence of bronchiectasis in four European countries

Rogers, G

Microbiota composition and disease severity in bronchiectasis

Rojas, E

Long-term randomized controlled trial to evaluate the efficacy of low expiration with the open glottis in the lateral posture in bronchiectasis

Rosales-Mayor, E

Risk factors for bronchiectasis exacerbations caused by multidrug-resistant microorganisms

Pneumonic vs. non-pneumonic exacerbations in bronchiectasis

Exacerbations by Pseudomonas aeruginosa in patients with bronchiectasis

Effects of hypertonic saline on sputum clearance in patients with bronchiectasis

Evaluation of two prognostic scores in adult patients with non-cystic fibrosis bronchiectasis

Royen, B

TAp73 is a central transcriptional regulator of airway multiciliogenesis and protects bronchial function

Rozsivalova, D

Study of population of patients with non-cystic bronchiectasis treated in the University Hospital of Olomouc, Czech Republic

Runken, MC

Treatment patterns associated with pseudomonas aeruginosa among patients with non-cystic fibrosis bronchiectasis in the US

The prevalence of non-cystic fibrosis bronchiectasis in the US

Healthcare cost and utilization before and after diagnosis of pseudomonas aeruginosa among patients with non-cystic fibrosis bronchiectasis in the US

Rusu, D

Combination of non CF-bronchiectasis and calcifications: a hallmark of high burden TB country

Rutherford, RM

Characterization of bronchiectasis in the elderly

Sabater, G

Long-term randomized controlled trial to evaluate the efficacy of low expiration with the open glottis in the lateral posture in bronchiectasis

Sadigov, A

Looking for Right Management for Patients Severe COPD associated with NON-CF Bronchiectasis:Where Is Rifht Way to GO?

Sáez, ME

Prevalence of bronchiectasis in four European countries

Salipalli, S

Why do some adults with PiMZ alpha1-antitrypin develop bronchiectasis?

Schild, D

TAp73 is a central transcriptional regulator of airway multiciliogenesis and protects bronchial function

Schwerk, N

Why do some adults with PiMZ alpha1-antitrypin develop bronchiectasis?

Serisier, D

A Phase 3 Study Design of Pulmaquin® in Non-Cystic Fibrosis Bronchiectasis (NCFBE) Patients Chronically Colonized with Pseudomonas aeruginosa (PA)

Shaan Goonoo, M

Antibiotic use in treatment of non-CF Bronchiectasis: A retrospective analysis

Sheehan, E

Plasmapheresis as rescue therapy in severe bronchiectasis with blocking anti pseudomonas antibodies

Shomroni, O

TAp73 is a central transcriptional regulator of airway multiciliogenesis and protects bronchial function

Shteinberg, M

Bronchiectasis with upper airways symptoms is associated with allergic features and frequent exacerbations

Sibila, O

Anti-Pseudomonas aeruginosa IgG Antibodies and Chronic Airway Infection in Non-Cystic Fibrosis Bronchiectasis

Siller, S

TAp73 is a central transcriptional regulator of airway multiciliogenesis and protects bronchial function

Simonet, P

Prevalence of bronchiectasis in four European countries

Sitar, J

Bronchictasis and asthma-case report

Skrbic, D

The incidence of metabolic syndrome in patients with non-CF bronchiectasis and chronic obstructive pulmonary disease

Characterization of bronchiectasis in the elderly

Computed tomography features in patients with non-cystic fibrosis bronchiectasis and COPD – one Institution experience

Smickova, P

Study of population of patients with non-cystic bronchiectasis treated in the University Hospital of Olomouc, Czech Republic

Smith, A

Anti-Pseudomonas aeruginosa IgG Antibodies and Chronic Airway Infection in Non-Cystic Fibrosis Bronchiectasis

Sokol, G

Effect of professional physiotherapy on patients with non CF bronchiectasis – a preliminary study

Sooronbaev, T

Problems of diagnosis and treatment of bronchiectasis in Kyrgyz Republic in conditions of limited health care resources

Sotgiu, G

Characterization of bronchiectasis in the elderly

Spickett, G

Plasmapheresis as rescue therapy in severe bronchiectasis with blocking anti pseudomonas antibodies

Sriraman, A

TAp73 is a central transcriptional regulator of airway multiciliogenesis and protects bronchial function

Steffen, H

TAp73 is a central transcriptional regulator of airway multiciliogenesis and protects bronchial function

Stockley, R

Plasmapheresis as rescue therapy in severe bronchiectasis with blocking anti pseudomonas antibodies

Stokic, E

The incidence of metabolic syndrome in patients with non-CF bronchiectasis and chronic obstructive pulmonary disease

Stoleski, S

Frequency and severity of chronic rhinosinusitis exacerbations in patients with bronchiectasis

Stone, G

Treatment patterns associated with pseudomonas aeruginosa among patients with non-cystic fibrosis bronchiectasis in the US

The prevalence of non-cystic fibrosis bronchiectasis in the US

Healthcare cost and utilization before and after diagnosis of pseudomonas aeruginosa among patients with non-cystic fibrosis bronchiectasis in the US

Suarez-Cuartin, G

Anti-Pseudomonas aeruginosa IgG Antibodies and Chronic Airway Infection in Non-Cystic Fibrosis Bronchiectasis

Surette, MG

Introducing the microbiome, lessons from the healthy lung and CF

Suzart-Woischnik, K

Prevalence of bronchiectasis in four European countries

Takemaru, KI

TAp73 is a central transcriptional regulator of airway multiciliogenesis and protects bronchial function

Te Ao, B

Bronchiectasis mortality in New Zealand, 2003 – 2013

Terpstra, L

Effects of long term ToBrAmycin InhalaTion SoluTion (TIS) once daiLy on Exacerbation rate in patients with non-cystic fibrosis bronchiectasis. A doubleblind, randomized, placebo controlled trial. The BATTLE study.

Torres, A

Risk factors for bronchiectasis exacerbations caused by multidrug-resistant microorganisms

Pneumonic vs. non-pneumonic exacerbations in bronchiectasis

Exacerbations by Pseudomonas aeruginosa in patients with bronchiectasis

Evaluation of two prognostic scores in adult patients with non-cystic fibrosis bronchiectasis

Torres-Marti, A

Effects of hypertonic saline on sputum clearance in patients with bronchiectasis

Vainshelboim, B

Lobar Distribution in Non-Cystic Fibrosis Bronchiectasis Predicts Bacteriologic Pathogen Treatment

Vanaudenaerde, B

Sensitization to Aspergillus fumigatus in COPD patients with and without bronchiectasis

Vandal, A

Bronchiectasis mortality in New Zealand, 2003 – 2013

van der Eerden, M

Translating treatments between COPD and bronchiectasis

Van Hoeyveld, E

Sensitization to Aspergillus fumigatus in COPD patients with and without bronchiectasis

Vendrell, M

Pneumonic vs. non-pneumonic exacerbations in bronchiectasis

Exacerbations by Pseudomonas aeruginosa in patients with bronchiectasis

Long-term randomized controlled trial to evaluate the efficacy of low expiration with the open glottis in the lateral posture in bronchiectasis

Vermeersch, K

Sensitization to Aspergillus fumigatus in COPD patients with and without bronchiectasis

Vidal, R

TAp73 is a central transcriptional regulator of airway multiciliogenesis and protects bronchial function

Vidal, S

Anti-Pseudomonas aeruginosa IgG Antibodies and Chronic Airway Infection in Non-Cystic Fibrosis Bronchiectasis

Vilaró-Casamiitjana, J

Effects of hypertonic saline on sputum clearance in patients with bronchiectasis

Villetti, G

CHI25243, a novel potent inhaled inhibitor of neutrophil elastase for the treatment of bronchiectasis and other chronic inflammatory lung disease

Vilozni, D

Effect of professional physiotherapy on patients with non CF bronchiectasis – a preliminary study

Wagner, D

Prevalence of Nontuberculous Mycobacterial Pulmonary Disease, Germany, 2009 – 2014

Wallace, R

12-Month Follow-up From Phase 2 Trial of Liposomal Amikacin for Inhalation (LAI) in Patients With Nontuberculous Mycobacterial (NTM) Lung Infection

Walshaw, M

Pseudomonas aeruginosa diversity and adaptation in the non-Cystic Fibrosis bronchiectasis lung

Wanner, A

A Phase 3 Study Design of Pulmaquin® in Non-Cystic Fibrosis Bronchiectasis (NCFBE) Patients Chronically Colonized with Pseudomonas aeruginosa (PA)

Wasser, W

Lobar Distribution in Non-Cystic Fibrosis Bronchiectasis Predicts Bacteriologic Pathogen Treatment

Wells, TJ

Plasmapheresis as rescue therapy in severe bronchiectasis with blocking anti pseudomonas antibodies

Welte, T

Editorial

Why do some adults with PiMZ alpha1-antitrypin develop bronchiectasis?

Prevalence of Nontuberculous Mycobacterial Pulmonary Disease, Germany, 2009 – 2014

PROGNOSIS – the German Bronchiectasis Registry

Wienken, M

TAp73 is a central transcriptional regulator of airway multiciliogenesis and protects bronchial function

Wildung, M

TAp73 is a central transcriptional regulator of airway multiciliogenesis and protects bronchial function

Wilms, E

The relationship between serum- and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment

Wilson, R

Baseline therapies for Bronchiectasis (non-CF etiology) vary by country – data from the RESPIRE1 trial of Ciprofloxacin Dry Powder for Inhalation (DPI)

Winstanley, C

Pseudomonas aeruginosa diversity and adaptation in the non-Cystic Fibrosis bronchiectasis lung

Winthrop, K

12-Month Follow-up From Phase 2 Trial of Liposomal Amikacin for Inhalation (LAI) in Patients With Nontuberculous Mycobacterial (NTM) Lung Infection

Baseline therapies for Bronchiectasis (non-CF etiology) vary by country – data from the RESPIRE1 trial of Ciprofloxacin Dry Powder for Inhalation (DPI)

Wong, C

Macrolides: known knowns, and known unknowns

Bronchiectasis mortality in New Zealand, 2003 – 2013

Xu, JF

Bronchiectasis in China: Present Situations and Challenges

The existence of asthma increases bronchiectasis exacerbation

Yang, JW

The existence of asthma increases bronchiectasis exacerbation

Yossef, A

MDCT severity score of bronchiectasis in correlation with pulmonary function tests

Zacherle, E

Treatment patterns associated with pseudomonas aeruginosa among patients with non-cystic fibrosis bronchiectasis in the US

The prevalence of non-cystic fibrosis bronchiectasis in the US

Healthcare cost and utilization before and after diagnosis of pseudomonas aeruginosa among patients with non-cystic fibrosis bronchiectasis in the US

Zatloukal, J

Study of population of patients with non-cystic bronchiectasis treated in the University Hospital of Olomouc, Czech Republic

Zlotogorski, A

STAT3-gain of function mutation as a cause of severe bronchiectasis and multi-organ autoimmunity; A case report

Zurawski, A

Editorial

PROGNOSIS – the German Bronchiectasis Registry

Šifrer, F

Bronchictasis and asthma-case report

Škrgat, S

Bronchictasis and asthma-case report